Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
LentiGlobin
Pharma
ASH: Bluebird's lovo-cel on track for submission in Q1 of 2023
After gaining FDA approvals for two gene therapies in the last four months, bluebird is set up for another BLA submission early next year.
Kevin Dunleavy
Dec 10, 2022 11:30am
Bluebird bio hits FDA clinical hold—again—for gene therapy
Dec 20, 2021 10:25am
Bluebird sued for patent infringement related to a gene therapy
Oct 25, 2021 10:51am
Bluebird bio's Zynteglo bounces back in Europe
Jul 9, 2021 11:57am
Bluebird tanks with FDA delay of LentiGlobin in sickle cell
Nov 5, 2020 10:58am
